PURPOSE: In this study, cationic mannosylated nanostructured lipid carriers (Man-NLCs) were developed for the targeted delivery of rifampicin to alveolar macrophages. METHODS: Rifampicin loaded Man-NLCs (RFP-Man-NLCs) and rifampicin loaded unmodified nanostructured lipid carriers (REP-NLCs) were prepared using thin film homogenization method and characterized by particle size, polydispersity index, zeta potential, transmission electron microscopy, encapsulation efficiency, pharmacokinetics, biodistribution, cell specific targeting, cytotoxicity and inflammatory response. RESULTS: RFP-Man-NLCs and REP-NLCs obtained displayed a size distribution around 160 nm (PDI <0.30) with positive charges of approximately 30 mV. The encapsulation efficiency of RFP was above 90%. In the biodistribution study, both RFP-Man-NLCs and RFP-NLCs, compared with the commercially available rifampicin solution, displayed superior lung-targeting ability. Compared to REP-NLCs, RFP-Man-NLCs exhibited significantly higher uptake efficiency in NR8383 cells and alveolar macrophages, which achieved cell-specific targeting. In addition, RFP-Man-NLCs were demonstrated to be a safe formulation with minimum toxicity and no inflammatory response. CONCLUSIONS: RFP-Man-NLCs provided an alternative strategy for selectively delivering rifampicin to alveolar macrophages.
PURPOSE: In this study, cationic mannosylated nanostructured lipid carriers (Man-NLCs) were developed for the targeted delivery of rifampicin to alveolar macrophages. METHODS:Rifampicin loaded Man-NLCs (RFP-Man-NLCs) and rifampicin loaded unmodified nanostructured lipid carriers (REP-NLCs) were prepared using thin film homogenization method and characterized by particle size, polydispersity index, zeta potential, transmission electron microscopy, encapsulation efficiency, pharmacokinetics, biodistribution, cell specific targeting, cytotoxicity and inflammatory response. RESULTS:RFP-Man-NLCs and REP-NLCs obtained displayed a size distribution around 160 nm (PDI <0.30) with positive charges of approximately 30 mV. The encapsulation efficiency of RFP was above 90%. In the biodistribution study, both RFP-Man-NLCs and RFP-NLCs, compared with the commercially available rifampicin solution, displayed superior lung-targeting ability. Compared to REP-NLCs, RFP-Man-NLCs exhibited significantly higher uptake efficiency in NR8383 cells and alveolar macrophages, which achieved cell-specific targeting. In addition, RFP-Man-NLCs were demonstrated to be a safe formulation with minimum toxicity and no inflammatory response. CONCLUSIONS:RFP-Man-NLCs provided an alternative strategy for selectively delivering rifampicin to alveolar macrophages.
Authors: J D McKinney; K Höner zu Bentrup; E J Muñoz-Elías; A Miczak; B Chen; W T Chan; D Swenson; J C Sacchettini; W R Jacobs; D G Russell Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Estefania Grotz; Nancy Tateosian; Nicolas Amiano; Maximiliano Cagel; Ezequiel Bernabeu; Diego A Chiappetta; Marcela A Moretton Journal: Pharm Res Date: 2018-09-20 Impact factor: 4.200
Authors: Alexandre Cc Vieira; Luíse L Chaves; Marina Pinheiro; Domingos Ferreira; Bruno Sarmento; Salette Reis Journal: Int J Nanomedicine Date: 2016-06-03
Authors: Luis Ángel Ibarra-Sánchez; Ana Gámez-Méndez; Manuel Martínez-Ruiz; Erik Francisco Nájera-Martínez; Brando Alan Morales-Flores; Elda M Melchor-Martínez; Juan Eduardo Sosa-Hernández; Roberto Parra-Saldívar; Hafiz M N Iqbal Journal: J Drug Deliv Sci Technol Date: 2022-03-05 Impact factor: 3.981
Authors: Juan Manuel Coya; Laura De Matteis; Alexandre Giraud-Gatineau; Anne Biton; Inés Serrano-Sevilla; Anne Danckaert; Marie-Agnès Dillies; Brigitte Gicquel; Jesus M De la Fuente; Ludovic Tailleux Journal: J Nanobiotechnology Date: 2019-01-25 Impact factor: 10.435
Authors: Aristote B Buya; Bwalya A Witika; Alain M Bapolisi; Chiluba Mwila; Grady K Mukubwa; Patrick B Memvanga; Pedzisai A Makoni; Christian I Nkanga Journal: Pharmaceutics Date: 2021-11-30 Impact factor: 6.321